Diabetic Kidney Disease in Elderly Individuals

Medical Clinics of North America

Volumn 97, Issue 1, 2013, Pages 75-89

  Williams, Mark E ^a  

^a JOSLIN DIABETES CENTER   (United States)

Author keywords

Diabetes; Elderly individuals; Kidney disease

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN A1C;

AGING; ALBUMINURIA; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; GERIATRIC PATIENT; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY FUNCTION; KIDNEY HYPERTROPHY; KIDNEY TUBULE BASEMENT MEMBRANE; MICROALBUMINURIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN URINE LEVEL; REVIEW;

AGE FACTORS; AGED; BLOOD GLUCOSE; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE MANAGEMENT; GLOMERULAR FILTRATION RATE; HUMANS; HYPERGLYCEMIA; HYPERTENSION; KIDNEY; MEDICATION THERAPY MANAGEMENT; OUTCOME ASSESSMENT (HEALTH CARE); RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENIN-ANGIOTENSIN SYSTEM; RISK ADJUSTMENT; RISK FACTORS;

EID: 84871784944     PISSN: 00257125     EISSN: 15579859     Source Type: Journal    
DOI: 10.1016/j.mcna.2012.10.011     Document Type: Review

References (66)

1. Sloan F.A., Bethel A., Ruiz D., et al. The growing burden of diabetes mellitus in the U.S. elderly population. Arch Intern Med 2008, 168:192-199.
2. Covie C.C., Rust K.F., Ford E.S., et al. Full accounting of diabetes and pre-diabetes in the U.S. population in 1988-1994 and 2005-2006. Diabetes Care 2009, 32:287-294.
3. Zimmet P., Alberti K.G., Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001, 414:782-787.
4. Wild S., Roglic G., Gren A., et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27:1047-1053.
5. Rosner M., Abdel-Rahman E., Williams M.E. Geriatric nephrology: a new ASN priority. Clin J Am Soc Nephrol 2010, 5:936-942.
6. Coresh J. Prevalence of chronic kidney and decreased kidney function in the adult US population: third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003, 41:1-12.
7. Stevens L.A., Li S., Wang C., et al. Prevalence of CKD and comorbid illness in elderly patients in the United States: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis 2010, 55(Suppl 2):S23-S33.
8. Kurella M., Covinsky K.E., Collins A.J., et al. Octogenarians and nonagenarians starting dialysis in the United States. Ann Intern Med 2007, 146:177-183.
9. Van Dijk P.C., Jager K.J., Stengel B., et al. Renal replacement therapy for diabetic end-stage renal disease: data from 10 registries in Europe (1991-2000). Kidney Int 2005, 67:1489.
10. Letourneau I., Ouimet D., Dumont M., et al. Renal replacement in end-stage renal disease patients over 75 years old. Am J Nephrol 2003, 23(2):71-77.
11. Kurella M., Chertow G.M., Fried L.F., et al. Chronic kidney disease and cognitive impairment in the elderly: the health, aging, and body composition study. J Am Soc Nephrol 2005, 16(7):2127-2133.
12. Loc C.E., Oliver M.J., Su J., et al. Arteriovenous fistula outcomes in the era of the elderly dialysis population. Kidney Int 2005, 67:2462-2469.
13. Jefferson J.A., Alpers C.E. Should renal biopsies be performed in the very elderly?. Nat Rev Nephrol 2009, 5:561-562.
14. Martin J.E., Sheaff M.T. Renal ageing. J Pathol 2007, 21:198-205.
15. Zhou X.J., Rakheja D., Yu X., et al. The ageing kidney. Kidney Int 2008, 74:710-720.
16. Wiggins R.C. The spectrum of podocytopathies: a unifying view of glomerular diseases. Kidney Int 2007, 71:1205-1214.
17. Nair R., Bell J.M., Walker P.D. Renal biopsy in patients 80 years and older. Am J Kidney Dis 2004, 44:618-626.
18. Verzola D., Gandolfo M.T., Gaetani G., et al. Accelerated senescence in the kidneys of patients with type 2 diabetic nephropathy. Am J Physiol Renal Physiol 2008, 295:F1563-F1573.
19. Tsaih S.W., Pezzolesi M.G., Yuan R., et al. Genetic analysis of albuminuria in ageing mice and concordance with loci for human diabetic nephropathy found in a genome-wide association scan. Kidney Int 2010, 77:201-210.
20. Pezzolesi Z.M., Poznik G.D., Mychaleckyj J.C. Genome-wide association scan for diabetic nephropathy susceptibility genes in type 1 diabetes. Diabetes 2009, 58:1403-1410.
21. Semba R.D., Nicklett E.J., Ferrucci L. Does accumulation of advanced glycation end products contribute to the ageing phenotype?. J Gerontol A Biol Sci Med Sci 2010, 65(9):963-975.
22. Kasper M., Funk R.H. Age-related changes in cells and tissues due to advanced glycation end products (AGEs). Arch Gerontol Geriatr 2001, 32:233-243.
23. Mei C., Zheng F. Chronic inflammation potentiates kidney ageing. Semin Nephrol 2009, 29:555-568.
24. Vlassara H., Uribarri J., Ferrucci L., et al. Identifying advanced glycation end products as a major source of oxidants in ageing: implications for the management and/or prevention of reduced renal function in elderly persons. Semin Nephrol 2009, 29:594-603.
25. Vlassara H., Torreggiani M., Post J.B., et al. Role of oxidants/inflammation in declining renal function in chronic kidney disease and normal ageing. Kidney Int 2009, 76(Suppl 114):S3-S11.
26. Vora J.P., Chattington P.D., Ibrahin H. Clinical manifestations and natural history of diabetic nephropathy. Comprehensive clinical nephrology 2000, Elsevier.
27. Wasen E., Isoaho R., Mattila K., et al. Renal impairment associated with diabetes in the elderly. Diabetes Care 2004, 27:2648-2653.
28. Ibrahim H.N., Foley R., Tan L., et al. Long-term consequences of kidney donation. N Engl J Med 2009, 360:459-469.
29. Rodriguez-Puyol D. The aging kidney. Kidney Int 1998, 56:2247-2255.
30. Raymond N.T., Zehnder D., Smith S.C., et al. Elevated relative mortality risk with mild-to-moderate chronic kidney disease decreases with age. Nephrol Dial Transplant 2007, 22:3214-3220.
31. Kausz A.T. Chronic kidney disease in the older patient. Clin Geriatr 2004, 12:39-47.
32. Premaratne E., MacIsaac R.J., Tsalamandris C., et al. Renal hyperfiltration in type 2 diabetes: effect of age-related decline in glomerular filtration rate. Diabetologia 2005, 48:2486-2493.
33. de Zeeuw D. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004, 110:921-927.
34. Barzilay J. The relationship of cardiovascular risk factors to microalbuminuria in older adults with or without diabetes mellitus or hypertension: the cardiovascular health study. Am J Kidney Dis 2004, 44:25-34.
35. Williams M.E. Diabetic kidney disease in the older adult: an update. Aging Health 2009, 5:625-633.
36. United Kingdom Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853.
37. Shorr R.I., Franse L.V., Resnick H.E., et al. Glycemic control of older adults with type 2 diabetes: findings from the Third National Health and Nutrition Examination Survey, 1988-1994. J Am Geriatr Soc 2000, 48:264-267.
38. Whitmer R.A., Karter A.J., Yaffe K., et al. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA 2009, 301:1565-1572.
39. Kahn S.E. Glucose control in type 2 diabetes: still worthwhile and worth controlling. JAMA 2009, 301:1590-1592.
40. Brown A.F., Mangione C.M., Saliba D., et al. Guidelines for improving the care of the older person with diabetes mellitus. J Am Geriatr Soc 2003, 51:S265-S280.
41. Abaterusso C., Lupo A., Ortalda V., et al. Treating elderly people with diabetes and Stages 3 and 4 chronic kidney disease. Clin J Am Soc Nephrol 2008, 3:1185-1194.
42. Burrows N.R., Li Y., Geiss L.S. Incidence of treatment for end-stage renal disease among individuals with diabetes in the U.S. continue to decline. Diabetes Care 2010, 33:73-77.
43. KDOQI KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis 2007, 49(2 Suppl 2):S12-S154.
44. Tkac I. Effect of intensive glycemic control on cardiovascular outcomes and all-cause mortality in type 2 diabetes: overview and metaanalysis of five trials. Diabetes Res Clin Pract 2009, 86(Suppl 1):S57-S62.
45. The Action to Control Cardiovascular Risk in Diabetes Study Group Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545-2559.
46. The ADVANCE Collaborative Group Intensive blood glucose and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572.
47. Duckworth W., Abraira C., Moritz T., for the VADT Investigators, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009, 360:129-139.
48. Abrahamson M. A 74-year-old woman with diabetes. Clinical Crossroads. JAMA 2007, 297:196-204.
49. O'Hare A.M., Bertenthal D., Covinsky K.E., et al. Mortality risk stratification in chronic kidney disease: one size for all ages?. J Am Soc Nephrol 2006, 17:846-853.
50. Abbatecola A.M., Paolisso G., Corsonello A., et al. Antidiabetic oral treatment in older people: does frailty matter?. Drugs Aging 2009, 26(Suppl 1):53-62.
51. Chobanian A.V., Bakris G.L., Black H.R., et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 2003, 289:19-29.
52. Young J. Blood pressure and decline in kidney function: findings from the Systolic Hypertension in the Elderly Program (SHEP). J Am Soc Nephrol 2002, 13:276-282.
53. Kidney Disease Outcomes Quality Initiative (K/DOQI) KDOQI Clinical Practice Guidelines on hypertension and antihypertensive agents. Am J Kidney Dis 2004, 43(Suppl 1):4-194.
54. Lewis E., Hunsicker L.G., Bain R.P., et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993, 329:1456-1462.
55. Brenner B., Cooper M.E., de Zeeuw D., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869.
56. Lewis E., Hunsicker L.G., Clarke W.R., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851-860.
57. Rosen A.B., Karter A.J., Liu J.Y., et al. Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high-risk clinical and ethnic groups with diabetes. J Gen Intern Med 2004, 19:669-675.
58. Shahinfar S., Dickson T., Zhang Z., et al. Baseline predictors of end-stage renal disease risk in patients with type 2 diabetes and nephropathy: new lessons from the RENAAL study. Kidney Int 2005, 67(Suppl 93):S48-S51.
59. Parving H.H., Lehnert H., Brochner-Mortensen J., et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001, 345:870-878.
60. Winkelmayer W.C., Zhang Z., Shahinfar S., et al. Efficacy and safety of angiotensin II receptor blockade in elderly patients with diabetes. Diabetes Care 2006, 29:2210-2217.
61. Kramer H.J., Nguyen Q.D., Curhan G., et al. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA 2003, 289(24):3273-3277.
62. Hemmelgarn B.R., Zhang J., Manns B. Nephrology visits and health care resource use before and after reporting estimated glomerular filtration rate. JAMA 2010, 303(12):1151-1158.
63. Basi S., Lewis J. Microalbuminuria as a target to improve cardiovascular and renal outcomes. Am J Kidney Dis 2006, 47(6):927-946.
64. Borch-Johnsen K., Feldt-Rasmussen B., Strandgaard S., et al. Urinary albumin excretion: an independent predictor of ischemic heart disease. Arterioscler Thromb Vasc Biol 1996, 19:1992-1997.
65. Miettinen H., Haffner S.M., Lehto S., et al. Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects. Stroke 1996, 27:2033-2039.
66. Joss N., Ferguson C., Brown C., et al. Intensified treatment of patients with type 2 diabetes mellitus and overt nephropathy. QJM 2004, 97(4):219-227.